What is RapidPulse?
RapidPulse operates at the intersection of advanced engineering and neurovascular care. The company specializes in the development of sophisticated, minimally invasive medical devices specifically engineered to address the complexities of ischemic stroke. By focusing on vascular intervention, RapidPulse aims to improve patient outcomes through precision technology that reduces procedural trauma and enhances recovery times. Its market position is bolstered by a robust intellectual property portfolio and strategic partnerships with industry leaders, allowing the firm to bridge the gap between experimental medical science and practical clinical application in global healthcare systems.
How much funding has RapidPulse raised?
RapidPulse has raised a total of $73.5M across 3 funding rounds:
Series A
$15M
Other Financing Round
$10.5M
Series B
$48M
Series A (2021): $15M with participation from SYNTHEON Inc, Sante Ventures, Epidarex Capital, Hatteras Venture Partners, and Broadview Ventures
Other Financing Round (2022): $10.5M led by Epidarex Capital, Santé Ventures, Syntheon, Broadview Ventures, and Hatteras Venture Partners
Series B (2026): $48M supported by Hatteras Venture Partners, Epidarex Capital, Santé Ventures, TechWald Holding SpA, SYNTHEON, SBI Investment, S3 Ventures, Florida Opportunity Fund, and Medtronic
Key Investors in RapidPulse
Hatteras Venture Partners
A venture capital firm with over 25 years of experience, specializing in building transformative companies within the biotech, MedTech, and HealthTech sectors.
Epidarex Capital
A transatlantic venture capital firm focused on building breakthrough life science companies in emerging hubs through deep scientific and industry networks.
Santé Ventures
A privately held investment firm managing over $1 billion in capital, dedicated to innovative healthcare and technology companies that enhance patient health outcomes.
What's next for RapidPulse?
With the infusion of $48M, RapidPulse is well-positioned to scale its operations and advance its product pipeline through critical regulatory and clinical milestones. The company is expected to prioritize the expansion of its manufacturing capabilities and the acceleration of clinical trials to validate its next-generation vascular devices. Given the strategic nature of its recent capital, RapidPulse will likely focus on deepening its market penetration and exploring new therapeutic applications for its core technology. As the company matures, the focus will shift toward commercialization strategies and potential integration into broader cardiovascular and neurovascular care ecosystems, ensuring long-term value creation for its stakeholders and improved standards of care for stroke patients worldwide.
See full RapidPulse company page
